



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 18<sup>th</sup> May 2022

#### PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Dr T MacKenzie (TMc)	GP East Lancashire
Ms F Iqbal (FI)	Senior Pharmacist NHS BwD CCG
Dr F Mohamed (FM)	Consultant Acute Physician
Dr A Sibley (AS)	Paediatrics Consultant
Mr C Woods (CW)	Head of Contracting and Costing, Finance
Mrs H. Robinson (HR)	Divisional Lead Pharmacist – MEC
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes
Dr D Sebastian (DS)	Consultant Intensivist and Deputy DMD for SAS

#### IN ATTENDANCE:

Dr S Chadaide (SC)	Cardiology Consultant
Ms L Prince (LP)	Medicines Management Technician, EL CCG
Dr K Nizamuddin (KN)	Endocrinology Consultant
Dr A MacPherson (AM)	Palliative Care Consultant

#### 2022/76: APOLOGIES:

Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Dr S Bhattacharya (SB)	ED Consultant

#### 2022/077: DECLARATION OF INTEREST

Dr S Ramtoola

#### 2022/078: MINUTES OF MARCH TEAMS MEETING:

April 2022 Minutes Accepted



## 2022/079: MATTERS ARISING:

- a. **2022/006a: Zonisamide liquid:** expected number of patients likely to transfer out from secondary care is small. This drug is currently Red Traffic Light but the potential for IMOT supplying the medication is currently unsure due to capacity issues. It was agreed to switch to AMBER Traffic Light. Patients transferring out to Primary Care will be stabilised by the specialist. Any further dose adjustments in respect of age/growth/weight changes will be actioned in secondary care. A Principles and Guidance Framework is required and to include that a review at 6 months is required.

**Action:** item closed

**Traffic Light:** AMBER

- b. **2022/006c: Ethosuximide liquid:**

Comments as above.

**Action:** item closed

**Traffic Light:** AMBER

- c. **2022/059(a,b,c): Quattro Multifunctional Solution, Ote Clean 40 and Lens Plus OcuPure Saline:** IFR form forwarded to the requestor

**Action:** item closed

- d. **2022/059e: Parecoxib – Syringe pump policy update:** Acknowledged

**Action:** ELMMB website to be updated. Item closed

- e. **2022/063 (a,b): Tralokinumab FOC application and Upadacitinib FOC**

**application:** Local decision made not to commission in advance of imminent NICE guidance

**Action:** acknowledged. Item closed.

- f. **2022/068: Differences in RAG:** list discussed and formulary to be updated accordingly as agreed

**Action:** AB to feedback the three different RAG items and reasoning behind decision to LSCMMG.

## 2022/080: New Product Request

**Efmody® 5mg and 10mg tabs** (Hydrocortisone modified-release hard capsules). Requested by Dr Nizamuddin, Consultant in diabetes and endocrinology [as AMBER Traffic Light]. This is an expensive MR product in comparison to non-modified release tablets and is requested for use in adolescent patients aged 12 years and over and adults with congenital adrenal hyperplasia (CAH) who have sub optimal control on conventional treatment. Members agreed that this should be reviewed by LSCMMG for inclusion on formulary across the Lancashire ICS

**Action:** Dr Nizamuddin to provide more information on place in therapy and AB to submit updated new product request form to LSCMMG.



## 2022/081 Formulary Updates

- a. **Mexiletine 100mg and 200mg capsules** (Licenced version for ventricular arrhythmias). Currently an unlicensed product is RED traffic light on formulary and Dr Chadaide [Consultant cardiologist] is requesting it is switched to AMBER and replaced with the licensed product. Strengths 50mg and 100mg only.  
**Traffic Light: AMBER**
- b. **Budesonide 1mg and 0.5mg nebs:** requested by paediatric specialist pharmacist for treatment of persistent cough and wheeze associated with reversible airways disease; Treatment of Bronchopulmonary Dysplasia (BPD); Croup and Acute asthma in paediatric patients.  
**Resolved:** Approved for use in paediatrics only. **Traffic Light: AMBER**
- c. **Lidocaine 5% / Phenylephrine 0.5% nasal spray (2.5mLs):** requested by ENT& Max Fax specialist pharmacist for anaesthesia before nasal surgery, endoscopy, laryngoscopy, or removal of foreign bodies from the nose.  
**Resolved:** Approved for use **Traffic Light: RED**
- d. **Isosorbide Mononitrate MR** preparations: currently on formulary as prescribed by brand. Request by cardiology specialist to prescribe generically.  
**Resolved:** Approved. **Traffic Light: GREEN**
- e. **Saxenda 6mg/ml solution for injection 3ml pre-filled pens:** currently RED traffic light on formulary as an adjunct to weight management, requiring a specialist multidisciplinary treatment setting that is not available in the local area. This is a commissioning issue that has been discussed at LSCMMG, but feedback hasn't been received. The specialist service based in Blackpool can assess patients: but distance, numbers needing to access the service need to be explored. To remain RED traffic light until more locally commissioned alternative is explored.  
**ACTION:** LR to ask for feedback at next LSCMMG **Traffic Light: RED**
- f. **Hydrocortisone - 2.5 mg, 5 mg & 15 mg tabs:** Requested for adrenal replacement therapy patients only as an extra option when stabilising therapy.  
**Resolved:** Approved for use in adrenal replacement therapy only  
**Traffic Light: AMBER**
- g. **Slozem (Diltiazem):** now available and more cost-effective. Request to be included as 2<sup>nd</sup> line hospital use.  
**Resolved:** Approved. **Traffic Light: GREEN**
- h. **Oralieve® Moisturising Mouth Spray:** Request by MFOP Specialist Pharmacist to be added formulary for dry mouth in palliative care patients.  
**Resolved:** Approved. **Traffic Light: AMBER**



- i. **Sodieye 5% PF eye drops - 10ml** (sodium chloride 5% preservative free eye drops) Cost-effective formulation, prescribed by brand  
**Resolved:** Approved. **Traffic Light: AMBER**

#### 2022/082 LSCMMG Consultations - May 2022

Ryaltris for symptoms of moderate to severe seasonal and perennial allergic rhinitis.

This product is currently GREEN restricted on ELMMB

#### 2022/083 LSCMMG Recommendations – April 2022

Bempedoic acid with ezetimibe - updated background info

(<https://www.lancsmmg.nhs.uk/medicines-library/bempedoic-acid-with-ezetimibe/>)

**Resolved:** Acknowledged by ELMMB

#### 2022/084 Other items

**LSC Palliative Care Clinical Practice Summary 2nd Edition** - for info only  
**Community Anticipatory medication authorisation sheet guidance** - v4 - with annotations – updated in line with above

**Community Anticipatory medication authorisation sheet guidance** - v4 updated in line with above

**Resolved:** Acknowledged and to be uploaded to ELMMB and updated information disseminated to GPs in Primary Care

#### 2022/085 Other items

Olaparib Free of Charge Compassionate Use Scheme

**Resolved:** Approved

#### 2022/086 Other items

Pembrolizumab Free of Charge Compassionate Use Scheme

**Resolved:** Approved

#### 2022/087 Other items

Medicines to prescribe by brand name

(<https://www.sps.nhs.uk/articles/example-medicines-to-prescribe-by-brand-name-in-primary-care/>)

**Resolved:** Acknowledged



## 2022/088 Other items

Algorithm first line medication type 2 diabetes March 2022  
(<https://www.guidelines.co.uk/diabetes/nice-type-2-diabetes-guideline/252691.article>)

**Resolved**

## 2022/089 Other items

**Current and proposed RAG status for liothyronine** - output from LSCMMG liothyronine meeting.

**Action:** Dr SR to discuss with endocrinology team and provide feedback to AB to forward to LSCMMG.

## 2022/090 NICE Guidance - April 2022

**NG 217 – Epilepsies in children, young people and adults:** updated 27 April 2022

**NG215 – Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management in adults:** updated 20<sup>th</sup> April 2022

**NG 128 -Stroke and transient ischaemic attack in over 16s: diagnosis and initial management:** updated 13<sup>th</sup> April 2022

**Resolved:** Items acknowledged by ELMMB

## 2022/091 NICE Recommendations – March 2022

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma is recommended as an option by NICE. Approved in line with NICE TA783  
NHS England Commissioned **Traffic Light: RED**

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer is recommended as an option by NICE. Approved in line with NICE TA784  
NHS England Commissioned **Traffic Light: RED**

Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) NICE TA785 **Traffic Light: BLACK**

Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies is recommended as an option by NICE. Approved in line with NICE TA786  
NHS England Commissioned **Traffic Light: RED**



Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable is recommended as an option by NICE.

Approved in line with NICE TA787

NHS England Commissioned

**Traffic Light: RED**

**Resolved:** Items acknowledged by ELMMB

#### **2022/092 NICE Highly Specialised Technologies – April 2022**

HST 19 Elosulfase alfa for treating mucopolysaccharidosis type 4A

**Resolved:** item acknowledged by ELMMB

#### **2022/093 EAMS (Early access to medicines scheme) – April 2022**

a. Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan in the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

b. Risankizumab in the treatment of moderately to severely active Crohn's disease

**Resolved:** Item acknowledged by ELMMB

#### **Standing Items:**

#### **2022/094 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)**

DRAFT LSCMMG minutes 14.04.2022

**Resolved:** Minutes acknowledged.

**DATE OF NEXT MEETING – Wednesday 15<sup>th</sup> June 2022 12.45pm via 'Microsoft Teams'**



**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 18<sup>th</sup> May 2022**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2021/101b</b>	<b>ELMMB Membership</b> A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that	LR/VG	Sep 22
<b>2022/068</b>	<b>Differences in RAG:</b> AB to feedback the three different RAG items and reasoning behind decision to LSCMMG.	AB	June 22
<b>2022/080</b>	<b>Efmody® 5mg and 10mg tabs.</b> Dr Nizamuddin to provide more information regarding place in therapy and AB to submit updated new product request form to LSCMMG.	AB	June 22
<b>2022/081e</b>	<b>Saxenda 6mg/ml solution for injection 3ml pre-filled pens.</b> LR to ask for feedback from LSCMMG re commissioning position	LR	June 22
<b>2022/089</b>	<b>Current and proposed RAG status for liothyronine</b> Dr SR to gather endocrinology team opinion and AB to forward to LSCMMG.	AB	June 22